AUSTIN, Texas, Feb. 8, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML ), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30 p.m. ET to discuss preliminary results for its fourth quarter and full year 2012 ended December, 31, 2012. Select preliminary unaudited results will be issued in a press release prior to the call.
Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a question and answer period.
Date: Wednesday, February 20, 2013 Time: 4:30 p.m. Eastern time ( 1:30 p.m. Pacific time) Dial-In Number: 1-800-909-4761 International: 1-212-231-2934 Conference ID#: 21648726 Webcast: http://edge.media-server.com/m/p/e247e2q2/lan/en
The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860. A replay of the call will be available approximately two hours after the call through March 6, 2013. Toll-free replay number: 1-800-633-8284 International replay number: 1-402-977-9140 Replay pin number: 21648726 About Vermillion Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com. Investor Relations Contact: Liolios Group, Inc. Ron Both Tel 1-949-574-3860 firstname.lastname@example.org SOURCE Vermillion, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV